Cargando…

Psychopharmacological treatment in dissociative identity disorder (DID)

INTRODUCTION: Patients with dissociative identity disorder (DID) present two or more identities. Although it is a widely questioned diagnosis, it is currently found in the main DSM-5 and ICD-10 diagnostic manuals. So far there is no standard psychopharmacological treatment for people with this patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinilla, R., Sabaté, C. Rodríguez, Méndez, B. Ordóñez, Sotillos, A., Mata, A. Hernández
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471772/
http://dx.doi.org/10.1192/j.eurpsy.2021.412
_version_ 1784789153965146112
author Pinilla, R.
Sabaté, C. Rodríguez
Méndez, B. Ordóñez
Sotillos, A.
Mata, A. Hernández
author_facet Pinilla, R.
Sabaté, C. Rodríguez
Méndez, B. Ordóñez
Sotillos, A.
Mata, A. Hernández
author_sort Pinilla, R.
collection PubMed
description INTRODUCTION: Patients with dissociative identity disorder (DID) present two or more identities. Although it is a widely questioned diagnosis, it is currently found in the main DSM-5 and ICD-10 diagnostic manuals. So far there is no standard psychopharmacological treatment for people with this pathology. OBJECTIVES: Describe the pharmacological treatment associated with the clinical evolution of a patient with DID. METHODS: Follow-up was carried out in a mental health center for a year, undergoing psychopharmacological and psychotherapeutic treatment. The information is taken from the medical history. RESULTS: The patient presents with anxious and depressive symptoms. She was referred from primary care with 50mg sertraline without response. Dose was increased to 100mg without response. New management started with desvenlafaxine 100mg, associated with lorazepam, partially reducing the symptoms. Later, the patient presented self-referentiality, sounding of thought, began to describe frequent memory losses and a rebound in anxiety-depression symptoms, increasing the dose of desvenlafaxine to 200mg and introducing haloperidol to 1.5mg. Three months later, she presented showing another identity, active, aggressive, pythiatic, without evident anxious symptoms that she previously presented in a marked way. Desvenlafaxine was adjusted to 100mg and haloperidol to 0.5mg every 12 hours. The patient evolved favorably, decreasing anxiety, depressive symptoms and memory loss, in addition to disappearing psychotic symptoms. This treatment was sustained, keeping the patient psychopathological and functional stability and allowing a psychotherapeutic approach. CONCLUSIONS: Treatment with desvenlafaxine and haloperidol was favorable to maintain clinical stability and allow other therapeutic approaches.High dose of antidepressant could favor the expression of another identity of the patient. DISCLOSURE: No significant relationships. KEYWORD: antidepresive antipsicotic disociative memory-loss
format Online
Article
Text
id pubmed-9471772
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94717722022-09-29 Psychopharmacological treatment in dissociative identity disorder (DID) Pinilla, R. Sabaté, C. Rodríguez Méndez, B. Ordóñez Sotillos, A. Mata, A. Hernández Eur Psychiatry Abstract INTRODUCTION: Patients with dissociative identity disorder (DID) present two or more identities. Although it is a widely questioned diagnosis, it is currently found in the main DSM-5 and ICD-10 diagnostic manuals. So far there is no standard psychopharmacological treatment for people with this pathology. OBJECTIVES: Describe the pharmacological treatment associated with the clinical evolution of a patient with DID. METHODS: Follow-up was carried out in a mental health center for a year, undergoing psychopharmacological and psychotherapeutic treatment. The information is taken from the medical history. RESULTS: The patient presents with anxious and depressive symptoms. She was referred from primary care with 50mg sertraline without response. Dose was increased to 100mg without response. New management started with desvenlafaxine 100mg, associated with lorazepam, partially reducing the symptoms. Later, the patient presented self-referentiality, sounding of thought, began to describe frequent memory losses and a rebound in anxiety-depression symptoms, increasing the dose of desvenlafaxine to 200mg and introducing haloperidol to 1.5mg. Three months later, she presented showing another identity, active, aggressive, pythiatic, without evident anxious symptoms that she previously presented in a marked way. Desvenlafaxine was adjusted to 100mg and haloperidol to 0.5mg every 12 hours. The patient evolved favorably, decreasing anxiety, depressive symptoms and memory loss, in addition to disappearing psychotic symptoms. This treatment was sustained, keeping the patient psychopathological and functional stability and allowing a psychotherapeutic approach. CONCLUSIONS: Treatment with desvenlafaxine and haloperidol was favorable to maintain clinical stability and allow other therapeutic approaches.High dose of antidepressant could favor the expression of another identity of the patient. DISCLOSURE: No significant relationships. KEYWORD: antidepresive antipsicotic disociative memory-loss Cambridge University Press 2021-08-13 /pmc/articles/PMC9471772/ http://dx.doi.org/10.1192/j.eurpsy.2021.412 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Pinilla, R.
Sabaté, C. Rodríguez
Méndez, B. Ordóñez
Sotillos, A.
Mata, A. Hernández
Psychopharmacological treatment in dissociative identity disorder (DID)
title Psychopharmacological treatment in dissociative identity disorder (DID)
title_full Psychopharmacological treatment in dissociative identity disorder (DID)
title_fullStr Psychopharmacological treatment in dissociative identity disorder (DID)
title_full_unstemmed Psychopharmacological treatment in dissociative identity disorder (DID)
title_short Psychopharmacological treatment in dissociative identity disorder (DID)
title_sort psychopharmacological treatment in dissociative identity disorder (did)
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471772/
http://dx.doi.org/10.1192/j.eurpsy.2021.412
work_keys_str_mv AT pinillar psychopharmacologicaltreatmentindissociativeidentitydisorderdid
AT sabatecrodriguez psychopharmacologicaltreatmentindissociativeidentitydisorderdid
AT mendezbordonez psychopharmacologicaltreatmentindissociativeidentitydisorderdid
AT sotillosa psychopharmacologicaltreatmentindissociativeidentitydisorderdid
AT mataahernandez psychopharmacologicaltreatmentindissociativeidentitydisorderdid